Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2022 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
January 13, 2022 07:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Transformative acquisition significantly expands Salarius’ oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area...
February 11, 2021 19:00 ET | Source: Fior Markets

Global Hematological Cancers Therapeutics Market Is Expected to Reach USD 82.40 billion by 2028 : Fior Markets

Newark, NJ, Feb. 11, 2021 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global haematological cancer therapeutics market is expected to grow from USD 37.88 billion in 2020 and...
November 11, 2020 12:26 ET | Source: Telo Genomics Corp.

Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’s Disease

TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has received final approval and grant of three of its pending...
July 13, 2020 11:00 ET | Source: Notable Labs

Notable to Host July 23 Webinar with Stanford Cancer Institute and MDS Foundation: Emerging Treatment Approaches for Higher Risk Myelodysplastic Syndromes

FOSTER CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...
June 23, 2020 11:00 ET | Source: Notable Labs

Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

FOSTER CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...